Targeted Strategies for Today's Evolving Markets

• Platinum prices have recently reached their highest levels in more than two years.
• Palladium has also seen renewed interest as industrial demand stabilizes and inflation pressures persist.
• Platinum Group Metals Ltd. stands out due to its advanced-stage project, strong partnerships and commitment to innovation.

In recent weeks, platinum and palladium prices have gained considerable momentum, driven largely by a resurgence in demand from China’s jewelry sector and increasing concern over global supply constraints. Platinum Group Metals (NYSE American: PLG) (TSX: PTM), a development-stage mining company focused exclusively on platinum group metals (“PGMs”), is well positioned to capitalize on these favorable conditions. With a strong asset base and an advanced development project in South Africa, the company is pursuing a strategic path toward becoming an important supplier in a resurging PGM market.

Platinum prices have recently reached their highest levels in more than two years, trading above $1,095 per ounce, up more than 20% year-to-date (https://ibn.fm/GAzra). This rally has been fueled by a notable uptick in Chinese demand, particularly for platinum jewelry, which had previously lagged behind gold due to shifting consumer preferences. According to the World Platinum Investment Council (“WPIC”), China’s jewelry demand for platinum is expected to grow by 5% in 2025, reaching approximately 2.1 million ounces, as consumers take advantage of platinum’s price discount relative to gold. The shift follows a significant run-up in gold prices, leading value-conscious buyers back to platinum, which many consider to have similar aesthetic appeal and long-term intrinsic value (https://ibn.fm/m69AL, https://ibn.fm/cXDkM).

At the same time, palladium — a sister metal to platinum and an essential component in automotive catalytic converters — has also seen renewed interest as industrial demand stabilizes and inflation pressures persist (https://ibn.fm/Ww9BQ). China’s continued investment in automobile production, alongside gradual post-pandemic global recovery in vehicle manufacturing, has supported palladium’s rebound. Moreover, both metals are integral to emerging technologies such as hydrogen fuel cells and next-generation batteries, adding future demand potential beyond traditional uses.

Against this backdrop, Platinum Group Metals is making meaningful strides through its flagship Waterberg Project, a large-scale palladium-dominant deposit located on the Northern Limb of South Africa’s renowned Bushveld Igneous Complex. The company holds an effective 50.16% interest in the project, which is joint ventured with industry heavyweights Impala Platinum Holdings Limited (“Implats”), Hanwa Co. Ltd. and the Japan Organization for Metals and Energy Security (“JOGMEC”).

The Waterberg Project represents one of the few large-scale, greenfield PGM developments globally and is uniquely designed for mechanized, bulk underground mining. This differentiates it from traditional labor-intensive operations and makes it more attractive from a cost, safety and scalability perspective. A 2024 update to the Definitive Feasibility Study (“DFS”) outlined a 20% increase in proven and probable mineral reserves, extending the mine’s estimated life from 45 years to 54 years and confirming 23.4 million 4E ounces (platinum, palladium, rhodium, and gold) in reserves (https://ibn.fm/IBshz). The DFS also cited an after-tax net present value (“NPV”) of $569 million and an internal rate of return (“IRR”) of 14.2% using long-term consensus pricing, figures that underscore the project’s economic viability.

Beyond mining, Platinum Group Metals is investing in the future of PGMs through its partnership with Valterra Platinum to develop next-generation battery technologies (https://ibn.fm/DAcyx). This collaboration is focused on leveraging PGMs in energy storage applications, specifically targeting advancements in lithium-sulfur battery technology. Such innovations could open up entirely new demand verticals for platinum and palladium, aligning with global decarbonization trends and increasing interest in alternative energy storage systems.

While many mining companies are still navigating the regulatory and funding challenges of bringing new operations online, Platinum Group Metals stands out due to its advanced-stage project, strong partnerships and commitment to innovation. As global markets look to diversify away from risky supply chains and reduce dependence on any single geographic source, the Waterberg Project’s location and development plan make it a strategically important resource in the global PGM landscape.

The company’s progress is well timed. With China’s demand for platinum jewelry showing strong signs of recovery, and both platinum and palladium gaining traction across industrial and clean energy applications, the market outlook is increasingly favorable for companies capable of delivering high-quality supply. Platinum Group Metals is not only responding to today’s demand surge but also preparing to support the next phase of global economic and technological evolution with responsibly sourced, strategically important metals.

For more information, visit www.PlatinumGroupMetals.net.

NOTE TO INVESTORS: The latest news and updates relating to PLG are available in the company’s newsroom at https://ibn.fm/PLG

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

• HeartBeam has developed the first cable-free system capable of synthesizing a 12-lead ECG from 3D, non-coplanar electrical signals captured in real time.
• Patients can have the HeartBeam System with them at all times, ready to record an ECG in 30 seconds at home or anywhere when they feel symptoms to reduce delays in care.
• The HeartBeam System is now FDA cleared for arrhythmia assessment, with additional FDA review underway for its 12-lead ECG synthesis software for the same indication.
• A recent partnership with AccurKardia enhances HeartBeam’s arrhythmia solution with an FDA-cleared automated rhythm interpretation software.
• HeartBeam holds 20 issued patents, with additional allowed and pending applications, protecting its proprietary hardware, software, and algorithmic capabilities.
• Commercial launch is expected to be imminent, targeting a $500 million concierge SAM and broader multibillion-dollar patient pay market, supported by a high-margin, recurring revenue model.

HeartBeam (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. The company is creating the first ever cable-free synthesized 12-lead ECG platform designed to give patients the ability to record their symptoms the moment they occur, wherever they are. By providing synthesized, 12-lead ECG data, physicians can quickly assess the symptoms and ensure patients get the care they need in a timely manner. It also eliminates the need for wires, complex setup, or clinical staff, thus allowing synthesized 12-lead ECG signals to be accessible outside of a medical setting.

HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection but also unlocks future capabilities in ischemia detection, AI-assisted analysis, and longitudinal cardiac trend tracking.

The HeartBeam System is now FDA cleared for arrhythmia assessment, following foundational 510(k) clearance granted in December 2024. The company submitted a 510(k) application for its 12-lead ECG synthesis software in January 2025 for arrhythmia assessment. As it approaches commercialization, HeartBeam is executing a multi-phase go-to-market strategy with initial U.S. rollout plans and a focus on high-margin, recurring revenue.

The company is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship product is a credit card-sized, cable-free device designed to capture ECG signals in three non-coplanar directions and transform them into synthesized 12-lead ECGs. This novel form factor integrates a smartphone app, cloud connectivity, and a physician portal, enabling patients to record cardiac events at the moment symptoms occur and physicians to assess and triage in near real time.

The device is supported by an expanding software ecosystem. A key component of this is HeartBeam’s proprietary 12-lead ECG synthesis software, which met its clinical endpoint in the  VALID-ECG pivotal study with 93.4% manual diagnostic agreement for arrhythmia assessment. This software is currently under FDA review and is designed to deliver clinical-grade arrhythmia diagnostic capabilities outside of traditional healthcare environments.

In April 2025, HeartBeam announced a strategic partnership with AccurKardia to incorporate its FDA-cleared ECG analysis software, AccurECG(TM), into HeartBeam’s offering. This integration is expected to enhance automated rhythm interpretation, streamline physician workflows, and improve diagnostic speed and accuracy.

Additional form factors are under development, including an on-demand synthesized 12-lead patch with issued patents, intended to serve the extended-wear market segment. These complementary offerings are intended to support chronic disease management and continuous monitoring applications, broadening HeartBeam’s total product ecosystem in the future.

Market Opportunity

HeartBeam is targeting large and growing segments within the $20 billion+ global cardiac monitoring and diagnostics market. According to the company’s own materials, the U.S. concierge care segment alone represents a $500 million serviceable addressable market (“SAM”), comprising approximately 1.5 million patients—500,000 of whom are at elevated cardiac risk. This initial focus provides a strategic entry point for cash-pay and early adoption.

Expanding beyond this niche, HeartBeam identifies a $1.3 billion to $2.6 billion annual opportunity in the broader U.S. direct patient pay market, driven by more than 2.6 million high-income individuals aged 35–74 with elevated cardiac risk. For comparison, more than 2.5 million Oura rings and over 3 million AliveCor Kardia devices have been sold, demonstrating strong consumer willingness to adopt personal cardiac technologies.

HeartBeam’s long-term opportunity is significantly larger. The company estimates that over 20 million people in the U.S. are at high risk for myocardial infarction (“MI”), representing a total addressable market nearly 40 times greater than the concierge segment. Additionally, the company’s on-demand 12-lead patch aims to capture market share in the extended wear and mobile cardiac telemetry (“MCOT”) space, competing with incumbents like iRhythm, Boston Scientific, Philips, and Baxter.

Leadership Team

Robert P. Eno, Chief Executive Officer and Director, brings over 30 years of experience launching disruptive medical technologies and leading commercialization efforts. He has held executive roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular, and holds an MBA and BA from Stanford University.

Branislav Vajdic, PhD, President and Founder, is a seasoned innovator with over three decades of experience in technology and device development. He co-invented flash memory at Intel and led engineering teams responsible for the Pentium processor series. He previously served as CEO of NewCardio and holds a PhD in Electrical Engineering from the University of Minnesota.

Timothy Cruickshank, Chief Financial Officer, has over 15 years of experience in financial and strategic leadership roles. Formerly CFO at ImpediMed, he transformed the company into a SaaS-driven model. He holds an MBA from Keller Graduate School and a BS in Accounting from Syracuse University.

Peter J. Fitzgerald, MD, PhD, Chief Medical Officer, is a Stanford professor emeritus and interventional cardiologist with leadership in over 175 clinical trials and 24 medical startups. He co-founded TriVentures and has advised the FDA for over 20 years.

Ken Persen, Chief Technology Officer, has more than 25 years of experience in cardiac and digital health technology, including founding LIVMOR and leadership roles at Guidant and Cameron Health. He specializes in system design and product engineering for connected cardiac solutions.

For more information, visit the company’s website at www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN